Chapter 6 Proton Magnetic Resonance Spectroscopy In Dementias And Mild Cognitive Impairment

International Review of Neurobiology

Volumn 84, Issue , 2009, Pages 105-131

  Griffith, H Randall ^a,b,c   Stewart, Christopher C ^c   den Hollander, Jan A ^c  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; CHOLINE; CREATINE; DONEPEZIL; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; RIVASTIGMINE; XANOMELINE; DIAGNOSTIC AGENT; PROTON;

ALZHEIMER DISEASE; BRAIN DEGENERATION; BRAIN METABOLISM; CEREBROVASCULAR ACCIDENT; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE MARKER; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR DEPRESSION; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; NEUROPATHY; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PARKINSON DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; COGNITIVE DEFECT; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

COGNITION DISORDERS; DEMENTIA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PROTONS;

EID: 66249134238     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(09)00406-1     Document Type: Review

References (125)

1. Aarsland D., Litvan I., Salmon D., Galasko D., Wentzel-Larsen T., and Larsen J.P. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: Comparison with progressive supranuclear palsy and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74 9 (2003) 1215-1220
2. Ackl N., Ising M., Schreiber Y.A., Atiya M., Sonntag A., and Auer D.P. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci. Lett. 384 1-2 (2005) 23-28
3. Adalsteinsson E., Sullivan E.V., Kleinhans N., Spielman D.M., and Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 355 9216 (2000) 1696-1697
4. 1H-MRS at 0.5 T. Neurology 56 6 (2001) 737-742
5. Arends Y.M., Duyckaerts C., Rozemuller J.M., Eikelenboom P., and Hauw J.J. Microglia, amyloid and dementia in alzheimer disease. A correlative study. Neurobiol. Aging 21 1 (2000) 39-47
6. Bartha R., Smith M., Rupsingh R., Rylett J., Wells J.L., and Borrie M.J. High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 3 (2008) 786-793
7. Bartnik Olson B.L., Holshouser B.A., Britt III W., Mueller C., Baqai W., Patra S., Petersen F., and Kirsch W.M. Longitudinal Metabolic and Cognitive Changes in Mild Cognitive Impairment Patients. Alzheimer. Dis. Assoc. Disord (2008)
8. Bartres-Faz D., Junque C., Clemente I.C., Lopez-Alomar A., Bargallo N., Mercader J.M., and Moral P. Relationship among (1)H-magnetic resonance spectroscopy, brain volumetry and genetic polymorphisms in humans with memory impairment. Neurosci. Lett. 327 3 (2002) 177-180
9. Benecke R. Diffuse Lewy body disease - a clinical syndrome or a disease entity?. J. Neurol. 250 Suppl 1 (2003) 39-42
10. Block W., Jessen F., Traber F., Flacke S., Manka C., Lamerichs R., Keller E., Heun R., and Schild H. Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease. Arch. Neurol. 59 5 (2002) 828-834
11. Bowen B.C., Block R.E., Sanchez-Ramos J., Pattany P.M., Lampman D.A., Murdoch J.B., and Quencer R.M. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am. J. Neuroradiol. 16 1 (1995) 61-68
12. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl) 82 4 (1991) 239-259
13. Braak H., Ghebremedhin E., Rub U., Bratzke H., and Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318 1 (2004) 121-134
14. Brand A., Richter-Landsberg C., and Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev. Neurosci. 15 3-5 (1993) 289-298
15. Brooks D.J., and Piccini P. Imaging in Parkinson's disease: The role of monoamines in behavior. Biol. Psychiatry 59 10 (2006) 908-918
16. Catani M., Cherubini A., Howard R., Tarducci R., Pelliccioli G.P., Piccirilli M., Gobbi G., Senin U., and Mecocci P. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 12 11 (2001) 2315-2317
17. Catani M., Mecocci P., Tarducci R., Howard R., Pelliccioli G.P., Mariani E., Metastasio A., Benedetti C., Senin U., and Cherubini A. Proton magnetic resonance spectroscopy reveals similar white matter biochemical changes in patients with chronic hypertension and early Alzheimer's disease. J. Am. Geriatr. Soc. 50 10 (2002) 1707-1710
18. 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res. 1003 1-2 (2004) 26-35
19. Chantal S., Labelle M., Bouchard R.W., Braun C.M., and Boulanger Y. Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease. Arch. Neurol. 59 6 (2002) 955-962
20. Chen J.G., Charles H.C., Barboriak D.P., and Doraiswamy P.M. Magnetic resonance spectroscopy in Alzheimer's disease: Focus on N-acetylaspartate. Acta. Neurol. Scand. Suppl. 176 (2000) 20-26
21. Cheng L.L., Newell K., Mallory A.E., Hyman B.T., and Gonzalez R.G. Quantification of neurons in Alzheimer and control brains with ex vivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology. Magn. Reson. Imaging 20 7 (2002) 527-533
22. Christiansen P., Schlosser A., and Henriksen O. Reduced N-acetylaspartate content in the frontal part of the brain in patients with probable Alzheimer's disease. Magn. Reson. Imaging 13 3 (1995) 457-462
23. Cordato N.J., Halliday G.M., Harding A.J., Hely M.A., and Morris J.G. Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Ann. Neurol. 47 6 (2000) 718-728
24. Coulthard E., Firbank M., English P., Welch J., Birchall D., O'Brien J., and Griffiths T.D. Proton magnetic resonance spectroscopy in frontotemporal dementia. J. Neurol. 253 7 (2006) 861-868
25. Cummings J.L., Vinters H.V., Cole G.M., and Khachaturian Z.S. Alzheimer's disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 51 1 Suppl 1 (1998) S2-S17 discussion S65-17
26. Dickson D. Alzheimer-Parkinson disease overlap: Neuropathology. In: Clark C., and Trojanowski J. (Eds). Neurodegenerative dementias (2000), McGraw-Hill, New York City 247-259
27. Dickson D.W. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 56 4 (1997) 321-339
28. Dixon R.M., Bradley K.M., Budge M.M., Styles P., and Smith A.D. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain 125 Pt 10 (2002) 2332-2341
29. Doraiswamy P.M., Charles H.C., and Krishnan K.R. Prediction of cognitive decline in early Alzheimer's disease. Lancet 352 9141 (1998) 1678
30. Ernst T., Chang L., Melchor R., and Mehringer C.M. Frontotemporal dementia and early Alzheimer disease: Differentiation with frontal lobe H-1 MR spectroscopy. Radiology 203 3 (1997) 829-836
31. Fenili D., Brown M., Rappaport R., and McLaurin J. Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J. Mol. Med. 85 6 (2007) 603-611
32. Firbank M.J., Harrison R.M., and O'Brien J.T. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement. Geriatr. Cogn. Disord. 14 2 (2002) 64-76
33. Franczak M., Prost R.W., Antuono P.G., Mark L.P., Jones J.L., and Ulmer J.L. Proton magnetic resonance spectroscopy of the hippocampus in patients with mild cognitive impairment: A pilot study. J. Comput. Assist. Tomogr. 31 5 (2007) 666-670
34. Frederick B., Satlin A., Wald L.L., Hennen J., Bodick N., and Renshaw P.F. Brain proton magnetic resonance spectroscopy in Alzheimer disease: Changes after treatment with xanomeline. Am. J. Geriatr. Psychiatry. 10 1 (2002) 81-88
35. Frederick B.B., Satlin A., Yurgelun-Todd D.A., and Renshaw P.F. In vivo proton magnetic resonance spectroscopy of Alzheimer's disease in the parietal and temporal lobes. Biol. Psychiatry. 42 2 (1997) 147-150
36. Galvin J.E., Pollack J., and Morris J.C. Clinical phenotype of Parkinson disease dementia. Neurology 67 9 (2006) 1605-1611
37. Ganguli M., Dodge H., Shen C., and DeKosky S.T. Mild cognitive impairment, amnestic type: An epidemiological study. Neurology 63 (2004) 115-121
38. Garcia Santos J.M., Gavrila D., Antunez C., Tormo M.J., Salmeron D., Carles R., Jimenez Veiga J., Parrilla G., Torres del Rio S., Fortuna L., and Navarro C. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey. Dement. Geriatr. Cogn. Disord. 26 1 (2008) 15-25
39. Garrard P., Schott J.M., MacManus D.G., Hodges J.R., Fox N.C., and Waldman A.D. Posterior cingulate neurometabolite profiles and clinical phenotype in frontotemporal dementia. Cogn. Behav. Neurol. 19 4 (2006) 185-189
40. Godbolt A.K., Waldman A.D., MacManus D.G., Schott J.M., Frost C., Cipolotti L., Fox N.C., and Rossor M.N. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 66 5 (2006) 718-722
41. Gomez-Isla T., Growdon W.B., McNamara M., Newell K., Gomez-Tortosa E., Hedley-Whyte E.T., and Hyman B.T. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 53 9 (1999) 2003-2009
42. Griffith H.R., den Hollander J.A., Okonkwo O.C., O'Brien T., Watts R.L., and Marson D.C. Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia (2008), Alzheimer's & Dementia In press
43. Griffith H.R., den Hollander J.A., Okonkwo O.C., O'Brien T., Watts R.L., and Marson D.C. Brain N-acetylaspartate is Reduced in Parkinson Disease With Dementia. Alzheimer. Dis. Assoc. Disord. 22 1 (2008) 54-60
44. Griffith H.R., den Hollander J.A., Stewart C.C., Evanochko W.T., Buchthal S.D., Harrell L.E., Zamrini E.Y., Brockington J.C., and Marson D.C. Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease. NMR Biomed 20 (2007) 709-716
45. Griffith H.R., Hollander J.A., Okonkwo O., Evanochko W.T., Harrell L.E., Zamrini E.Y., Brockington J.C., and Marson D.C. Executive function is associated with brain proton magnetic resonance spectroscopy in amnestic mild cognitive impairment. J. Clin. Exp. Neuropsychol. 29 6 (2007) 599-609
46. Griffith H.R., Netson K.L., Harrell L.E., Zamrini E.Y., Brockington J.C., and Marson D.C. Amnestic mild cognitive impairment: Diagnostic outcomes and clinical prediction over a two-year time period. J. Int. Neuropsychol. Soc. 12 2 (2006) 166-175
47. Griffith H.R., Okonkwo O.C., den Hollander J.A., Belue K., Lanza S., Harrell L.E., Brockington J.C., Clark D.G., and Marson D.C. Brain proton MRS is correlated with financial abilities in patients with Alzheimer's disease. Brain Imaging & Behavior 1 (2007) 23-29
48. Griffith H.R., Okonkwo O.C., den Hollander J.A., Belue K., Lanza S., Harrell L.E., Brockington J.C., Clark D.G., and Marson D.C. Brain proton MRS is correlated with financial abilities in patients with Alzheimer's disease. Brain Imaging & Behavior 1 (2007) 23-29
49. Griffith H.R., Okonkwo O.C., O'Brien T., and Hollander J.A. Reduced brain glutamate in patients with Parkinson's disease. NMR Biomed. 21 4 (2008) 381-387
50. Griffith H.R., Stewart C.C., den Hollander J.A., Evanochko W.T., Buchthal S.D., Harrell L.E., Zamrini E.Y., Brockington J.C., and Marson D.C. In-vivo 3T 1H Magnetic Resonance Spectroscopy of the Brain Reveals Elevated Scyllo-inositol in Patients with Mild Alzheimer's Disease. Paper presented at the Proceedings of the International Society of Magnetic Resonance in Medicine (2006), Seattle, WA
51. Hattori N., Abe K., Sakoda S., and Sawada T. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport 13 1 (2002) 183-186
52. Herminghaus S., Frolich L., Gorriz C., Pilatus U., Dierks T., Wittsack H.J., Lanfermann H., Maurer K., and Zanella F.E. Brain metabolism in Alzheimer disease and vascular dementia assessed by in vivo proton magnetic resonance spectroscopy. Psychiatry. Res. 123 3 (2003) 183-190
53. Heun R., Schlegel S., Graf-Morgenstern M., Tintera J., Gawehn J., and Stoeter P. Proton magnetic resonance spectroscopy in dementia of Alzheimer type. Int. J. Geriatr. Psychiatry. 12 3 (1997) 349-358
54. Holmes C., Cairns N., Lantos P., and Mann A. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br. J. Psychiatry 174 (1999) 45-50
55. Jessen F., Block W., Traber F., Keller E., Flacke S., Lamerichs R., Schild H.H., and Heun R. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 57 5 (2001) 930-932
56. Jessen F., Block W., Traber F., Keller E., Flacke S., Papassotiropoulos A., Lamerichs R., Heun R., and Schild H.H. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 55 5 (2000) 684-688
57. Jessen F., Traeber F., Freymann K., Maier W., Schild H.H., and Block W. Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 67 3 (2006) 528-530
58. Jones R.S., and Waldman A.D. 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. Neurol. Res. 26 5 (2004) 488-495
59. 1H magnetic resonance spectroscopy study at 4 Tesla. NMR. Biomed. 18 1 (2005) 51-55
60. 1H MRS study. Neurology 55 2 (2000) 210-217
61. Kantarci K., Knopman D.S., Dickson D.W., Parisi J.E., Whitwell J.L., Weigand S.D., Josephs K.A., Boeve B.F., Petersen R.C., and Jack Jr. C.R. Alzheimer disease: Postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 248 1 (2008) 210-220
62. Kantarci K., Petersen R.C., Boeve B.F., Knopman D.S., Tang-Wai D.F., O'Brien P.C., Weigand S.D., Edland S.D., Smith G.E., Ivnik R.J., Ferman T.J., Tangalos E.G., et al. 1H MR spectroscopy in common dementias. Neurology 63 8 (2004) 1393-1398
63. Kantarci K., Reynolds G., Petersen R.C., Boeve B.F., Knopman D.S., Edland S.D., Smith G.E., Ivnik R.J., Tangalos E.G., and Jack Jr. C.R. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: Comparison of 1.5 and 3 T. AJNR. Am. J. Neuroradiol. 24 5 (2003) 843-849
64. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J. Int. Neuropsychol. Soc. 8 7 (2002) 934-942
65. Kantarci K., Weigand S.D., Petersen R.C., Boeve B.F., Knopman D.S., Gunter J., Reyes D., Shiung M., O'Brien P.C., Smith G.E., Ivnik R.J., Tangalos E.G., et al. Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging. 28 9 (2007) 1330-1339
66. Kantarci K., Xu Y., Shiung M.M., O'Brien P.C., Cha R.H., Smith G.E., Ivnik R.J., Boeve B.F., Edland S.D., Kokmen E., Tangalos E.G., Petersen R.C., et al. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 14 4 (2002) 198-207
67. Kario K., Matsuo T., Hoshide S., Umeda Y., and Shimada K. Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study. Stroke 30 5 (1999) 1033-1037
68. Kattapong V.J., Brooks W.M., Wesley M.H., Kodituwakku P.W., and Rosenberg G.A. Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. Arch. Neurol. 53 7 (1996) 678-680
69. Kickler N., Krack P., Fraix V., Lebas J.F., Lamalle L., Durif F., Krainik A., Remy C., Segebarth C., and Pollak P. Glutamate measurement in Parkinson's disease using MRS at 3 T field strength. NMR. Biomed (2007)
70. Kizu O., Yamada K., Ito H., and Nishimura T. Posterior cingulate metabolic changes in frontotemporal lobar degeneration detected by magnetic resonance spectroscopy. Neuroradiology 46 4 (2004) 277-281
71. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55 3 (2004) 306-319
72. Klunk W.E., Panchalingam K., McClure R.J., Stanley J.A., and Pettegrew J.W. Metabolic alterations in postmortem Alzheimer's disease brain are exaggerated by Apo-E4. Neurobiol. Aging. 19 6 (1998) 511-515
73. Kovari E., Gold G., Herrmann F.R., Canuto A., Hof P.R., Bouras C., and Giannakopoulos P. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta. Neuropathol. (Berl) 106 1 (2003) 83-88
74. Krishnan K.R., Charles H.C., Doraiswamy P.M., Mintzer J., Weisler R., Yu X., Perdomo C., Ieni J.R., and Rogers S. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am. J. Psychiatry. 160 11 (2003) 2003-2011
75. Kwock L. Localized MR spectroscopy: Basic principles. Neuroimaging Clin. N. Am. 8 4 (1998) 713-731
76. Lazeyras F., Charles H.C., Tupler L.A., Erickson R., Boyko O.B., and Krishnan K.R. Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy. Psychiatry. Res. 82 2 (1998) 95-106
77. Litvan I., Mohr E., Williams J., Gomez C., and Chase T.N. Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 54 1 (1991) 25-29
78. MacKay S., Ezekiel F., Di Sclafani V., Meyerhoff D.J., Gerson J., Norman D., Fein G., and Weiner M.W. Alzheimer disease and subcortical ischemic vascular dementia: Evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology 198 2 (1996) 537-545
79. Magistretti P.J., and Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 354 1387 (1999) 1155-1163
80. Markesbery W.R., Schmitt F.A., Kryscio R.J., Davis D.G., Smith C.D., and Wekstein D.R. Neuropathologic substrate of mild cognitive impairment. Arch. Neurol. 63 1 (2006) 38-46
81. Martinez-Bisbal M.C., Arana E., Marti-Bonmati L., Molla E., and Celda B. Cognitive impairment: Classification by 1H magnetic resonance spectroscopy. Eur J. Neurol. 11 3 (2004) 187-193
82. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65 12 (2005) 1863-1872
83. McLaurin J., Golomb R., Jurewicz A., Antel J.P., and Fraser P.E. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. J. Biol. Chem. 275 24 (2000) 18495-18502
84. McMurtray A., Clark D.G., Christine D., and Mendez M.F. Early-onset dementia: frequency and causes compared to late-onset dementia. Dement. Geriatr. Cogn. Disord. 21 2 (2006) 59-64
85. Metastasio A., Rinaldi P., Tarducci R., Mariani E., Feliziani F.T., Cherubini A., Pelliccioli G.P., Gobbi G., Senin U., and Mecocci P. Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy. Neurobiol. Aging. 27 7 (2006) 926-932
86. Meyerhoff D.J., MacKay S., Constans J.M., Norman D., Van Dyke C., Fein G., and Weiner M.W. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Ann. Neurol. 36 1 (1994) 40-47
87. Mihara M., Hattori N., Abe K., Sakoda S., and Sawada T. Magnetic resonance spectroscopic study of Alzheimer's disease and frontotemporal dementia/Pick complex. Neuroreport 17 4 (2006) 413-416
88. Moats R.A., Ernst T., Shonk T.K., and Ross B.D. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn. Reson. Med. 32 1 (1994) 110-115
89. Modrego P.J., Fayed N., and Pina M.A. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am. J. Psychiatry. 162 4 (2005) 667-675
90. Modrego P.J., Pina M.A., Fayed N., and Diaz M. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: A nonrandomised controlled trial with magnetic resonance spectroscopy. CNS. Drugs. 20 10 (2006) 867-877
91. Molina J.A., Garcia-Segura J.M., Benito-Leon J., Gomez-Escalonilla C., del Ser T., Martinez V., and Viano J. Proton magnetic resonance spectroscopy in dementia with Lewy bodies. Eur. Neurol. 48 3 (2002) 158-163
92. Mueller S.G., Schuff N., and Weiner M.W. Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS. NMR. Biomed. 19 6 (2006) 655-668
93. Osaki Y., Morita Y., Fukumoto M., Akagi N., Yoshida S., and Doi Y. Three-dimensional stereotactic surface projection SPECT analysis in Parkinson's disease with and without dementia. Mov. Disord. 20 8 (2005) 999-1005
94. Parnetti L., Lowenthal D.T., Presciutti O., Pelliccioli G.P., Palumbo R., Gobbi G., Chiarini P., Palumbo B., Tarducci R., and Senin U. 1H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease. J. Am. Geriatr. Soc. 44 2 (1996) 133-138
95. Parnetti L., Tarducci R., Presciutti O., Lowenthal D.T., Pippi M., Palumbo B., Gobbi G., Pelliccioli G.P., and Senin U. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech. Ageing. Dev. 97 1 (1997) 9-14
96. Petersen R.C. Mild cognitive impairment: Transition between aging and Alzheimer's disease. Neurologia 15 3 (2000) 93-101
97. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256 3 (2004) 183-194
98. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., and Winblad B. Current concepts in mild cognitive impairment. Arch. Neurol. 58 12 (2001) 1985-1992
99. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., and Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch. Neurol. 56 3 (1999) 303-308
100. Pfefferbaum A., Adalsteinsson E., Spielman D., Sullivan E.V., and Lim K.O. In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. Arch. Gen. Psychiatry. 56 2 (1999) 185-192
101. Pletnikova O., West N., Lee M.K., Rudow G.L., Skolasky R.L., Dawson T.M., Marsh L., and Troncoso J.C. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol. Aging. 26 8 (2005) 1183-1192
102. Rai G.S., McConnell J.R., Waldman A., Grant D., and Chaudry M. Brain proton spectroscopy in dementia: An aid to clinical diagnosis. Lancet. 353 9158 (1999) 1063-1064
103. Rami L., Caprile C., Gómez-Ansón B., Sánchez-Valle R., Monte G.C., Bosch B., and Molinuevo J.L. Naming is associated with left temporal pole metabolite levels in neurodegenerative diseases. Dement. Geriatr. Cogn. Disord. 25 3 (2008) 212-217
104. Rami L., Gomez-Anson B., Bosch B., Sanchez-Valle R., Monte G.C., Villar A., and Molinuevo J.L. Cortical brain metabolism as measured by proton spectroscopy is related to memory performance in patients with amnestic mild cognitive impairment and Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 24 4 (2007) 274-279
105. Rami L., Gomez-Anson B., Sanchez-Valle R., Bosch B., Monte G.C., Llado A., and Molinuevo J.L. Longitudinal study of amnesic patients at high risk for Alzheimer's disease: Clinical, neuropsychological and magnetic resonance spectroscopy features. Dement. Geriatr. Cogn. Disord. 24 5 (2007) 402-410
106. Riederer P., and Hoyer S. From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J. Neural. Transm. 113 11 (2006) 1671-1677
107. Rose S.E., de Zubicaray G.I., Wang D., Galloway G.J., Chalk J.B., Eagle S.C., Semple J., and Doddrell D.M. A 1H MRS study of probable Alzheimer's disease and normal aging: Implications for longitudinal monitoring of dementia progression. Magn. Reson. Imaging. 17 2 (1999) 291-299
108. Rosen Y., and Lenkinski R.E. Recent advances in magnetic resonance neurospectroscopy. Neurotherapeutics 4 3 (2007) 330-345
109. Ross B., and Bluml S. Magnetic resonance spectroscopy of the human brain. Anat. Rec. 265 2 (2001) 54-84
110. Schubert F., Gallinat J., Seifert F., and Rinneberg H. Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla. Neuroimage 21 4 (2004) 1762-1771
111. Schuff N., Amend D., Ezekiel F., Steinman S.K., Tanabe J., Norman D., Jagust W., Kramer J.H., Mastrianni J.A., Fein G., and Weiner M.W. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 49 6 (1997) 1513-1521
112. Shonk T.K., Moats R.A., Gifford P., Michaelis T., Mandigo J.C., Izumi J., and Ross B.D. Probable Alzheimer disease: Diagnosis with proton MR spectroscopy. Radiology 195 1 (1995) 65-72
113. Storandt M., Grant E.A., Miller J.P., and Morris J.C. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology 59 7 (2002) 1034-1041
114. Strange K., Emma F., Paredes A., and Morrison R. Osmoregulatory changes in myo-inositol content and Na+/myo-inositol cotransport in rat cortical astrocytes. Glia 12 1 (1994) 35-43
115. Summerfield C., Gomez-Anson B., Tolosa E., Mercader J.M., Marti M.J., Pastor P., and Junque C. Dementia in Parkinson disease: A proton magnetic resonance spectroscopy study. Arch. Neurol. 59 9 (2002) 1415-1420
116. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., and Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30 4 (1991) 572-580
117. Tierney M.C., Szalai J.P., Snow W.G., Fisher R.H., Nores A., Nadon G., Dunn E., and St George-Hyslop P.H. Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study. Neurology 46 3 (1996) 661-665
118. Tiraboschi P., Hansen L.A., Alford M., Sabbagh M.N., Schoos B., Masliah E., Thal L.J., and Corey-Bloom J. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 54 2 (2000) 407-411
119. Valenzuela M.J., and Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 56 5 (2001) 592-598
120. Waldman A.D., and Rai G.S. The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: A proton magnetic resonance spectroscopy study. Neuroradiology 45 8 (2003) 507-512
121. Waldman A.D., Rai G.S., McConnell J.R., Chaudry M., and Grant D. Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people. Arch. Gerontol. Geriatr. 35 2 (2002) 137-142
122. Watanabe T., Akiguchi I., Yagi H., Onishi K., Kawasaki T., Shiino A., and Inubushi T. Proton magnetic resonance spectroscopy and white matter hyperintensities on magnetic resonance imaging in patients with Alzheimer's disease. Ann. N. Y. Acad. Sci. 977 (2002) 423-429
123. Weiss U., Bacher R., Vonbank H., Kemmler G., Lingg A., and Marksteiner J. Cognitive impairment: Assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy. J. Clin. Psychiatry. 64 3 (2003) 235-242
124. Wiederkehr S., Simard M., Fortin C., and van Reekum R. Comparability of the clinical diagnostic criteria for vascular dementia: A critical review. Part I. J Neuropsychiatry. Clin. Neurosci. 20 2 (2008) 150-161
125. Xuan X., Ding M., and Gong X. Proton magnetic resonance spectroscopy detects a relative decrease of N-acetylaspartate in the hippocampus of patients with dementia with Lewy bodies. J. Neuroimaging 18 2 (2008) 137-141